A PYMNTS Company

UK: CMA closes pharmacy cartel

By  |  November 18, 2018

The Competition and Markets Authority (CMA) has decided to close its investigation into the alleged anti-competitive agreements and concerted practices in relation to generic pharmaceutical products.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The watchdog announced  its decision is based on administrative priority grounds. The authority further stated that it has not reached a view on whether there is sufficient evidence of an infringement of competition law for it to issue a statement of objections to the parties under investigation.

    “This decision does not amount to a statement or finding as to whether the party to the investigation has infringed competition law, nor should any inference be made to that effect,” the authority announced in the closure statement.

    The CMA launched the investigation on October 10, 2017, and expanded the scope in July this year, amid the backdrop of rising generics prices that affected community pharmacies hard.

    Full Content: Pharmacy
    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.